US9980893B2ActiveUtilityA1

Dye composition comprising a 1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-7-amine compound

59
Assignee: OREALPriority: Dec 20, 2013Filed: Dec 19, 2014Granted: May 29, 2018
Est. expiryDec 20, 2033(~7.4 yrs left)· nominal 20-yr term from priority
A61Q 5/10C07D 471/04A61Q 5/065A61K 2800/4324A61K 8/494
59
PatentIndex Score
0
Cited by
54
References
20
Claims

Abstract

The invention relates to a 1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-7-amine compound of formula (I) below, addition salts thereof, optical isomers, geometrical isomers and tautomers thereof and/or solvates thereof: in which: .R 2 , R 3 , R 4 , R 5 , and R 7 independently represent: a hydrogen or halogen atom; a C 1 -C 4 alkyl radical; a C 1 -C 4 hydroxyalkyl radical; a carboxyl radical; a (C 1 -C 4 )alkoxycarbonyl radical; .R1 and R6, which may be identical or different, represent: hydrogen atom; C 1 -C 10 and preferably Ci-C6 alkyl radical,—optionally interrupted with one or more heteroatoms chosen from O and S or with one or more groups—NR and/or—optionally terminating with at least one group—NX 1 X 2 or at least one group —OX 3 , .X 1 and X2 independently denote—a hydrogen atom, a linear C 1 -C 6 alkyl radical, a branched C 3 -C 6 alkyl radical, a linear C 1 -C 6 hydroxyalkyl radical or a branched C 3 -C 6 hydroxyalkyl radical, X1 and X2 may form, with the nitrogen atom that bears them, a saturated or unsaturated 5- to 8-membered heterocycle, in which one of the ring members may be a heteroatom chosen from O, S and N; the said heterocycle possibly being substituted with one or more linear or branched C 1 -C 4 alkyl or C 1 -C 4 hydroxyalkyl radicals, .X3 denotes—a hydrogen atom—a linear C1-C4 or branched C3-C4 alkyl radical, and .R denotes—a hydrogen atom—a linear C1-C4 alkyl radical.

Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
       1. A 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazin-7-amine compound chosen from those of formula (I) or the addition salts thereof, optical isomers thereof, geometrical isomers thereof, tautomers thereof, or solvates thereof: 
       
         
           
           
               
               
           
         
       
       wherein:
 R 2 , R 3 , R 4 , R 5 , and R 7 , which are identical or different, are independently chosen from:
 a hydrogen or halogen atom; 
 a C 1 -C 4  alkyl group; 
 a C 1 -C 4  hydroxyalkyl group; 
 a carboxyl group; or 
 a (C 1 -C 4 )alkoxycarbonyl group; 
 
 R 1  and R 6 , which are identical or different, are chosen from:
 a hydrogen atom; or 
 a C 1 -C 10  or C 1 -C 6  alkyl group, optionally interrupted with at least one heteroatom chosen from O, S, or at least one —NR group, and/or optionally terminated with at least one —NX 1 X 2  group or a —OX 3  group, 
 
 X 1  and X 2 , which are identical or different, are independently chosen from:
 a hydrogen atom; 
 a linear C 1 -C 6  alkyl group; 
 a branched C 3 -C 6  alkyl group; 
 a linear C 1 -C 6  hydroxyalkyl group; or 
 a branched C 3 -C 6  hydroxyalkyl group; 
 or X 1  and X 2  form, together with the nitrogen atom that bears them, a saturated or unsaturated 5- to 8-membered heterocycle, wherein at least one ring member is optionally a heteroatom chosen from O, S, or N; and/or the heterocycle is optionally substituted with at least one linear or branched C 1 -C 4  alkyl or C 1 -C 4  hydroxyalkyl group; 
 
 X 3  is chosen from:
 a hydrogen atom; or 
 a linear C 1 -C 4  or branched C 3 -C 4  alkyl group; and 
 
 R is chosen from:
 a hydrogen atom; or 
 a linear C 1 -C 4  alkyl group. 
 
 
     
     
       2. The 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazin-7-amine compound according to  claim 1 , wherein R 2 , R 3 , R 4 , R 5 , and R 7 , which may be identical or different, are chosen from a hydrogen atom or a C 1 -C 4  alkyl group. 
     
     
       3. The 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazin-7-amine compound according to  claim 1 , wherein R 3 , R 4 , R 5 , and R 7  each represent a hydrogen atom. 
     
     
       4. The 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazin-7-amine compound according to  claim 1 , wherein:
 X 1  and X 2  independently denote:
 a linear C 1 -C 4  alkyl group or a branched C 3 -C 4  alkyl group, or 
 a linear C 1 -C 4  hydroxyalkyl group or a branched C 3 -C 4  hydroxyalkyl group, 
 
 or X 1  and X 2  form, together with the nitrogen atom that bears them, a saturated or unsaturated 5- to 7-membered heterocycle, wherein at least one ring member is optionally substituted with a heteroatom chosen from O, S, or N; and/or the heterocycle is optionally substituted with at least one linear or branched C 1 -C 4  alkyl or C 1 -C 4  hydroxyalkyl group. 
 
     
     
       5. The 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazin-7-amine compound according to  claim 1 , wherein:
 X 3  is a hydrogen atom; and 
 R is chosen from a hydrogen atom or a methyl group. 
 
     
     
       6. The 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazin-7-amine compound according to  claim 5 , wherein the saturated or unsaturated 5- to 7-membered heterocyclic group wherein at least one of the ring members is optionally substituted with a heteroatom chosen from O, S, or N is chosen from imidazole, piperazine, pyrrolidine, morpholine, or piperidine rings. 
     
     
       7. The 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazin-7-amine compound according to  claim 1 , wherein:
 X 3  is a hydrogen atom; and 
 R is a hydrogen atom. 
 
     
     
       8. The 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazin-7-amine compound according to  claim 1 , wherein R 1  and R 6  are identical and are chosen from a hydrogen atom or a C 1 -C 6  alkyl group, optionally terminating with at least one group chosen from a —NX 1 X 2  group or an —OH group,
 wherein X 1  and X 2  are independently chosen from:
 a linear C 1 -C 4  alkyl group; 
 a branched C 3 -C 4  alkyl group; 
 a linear C 1 -C 4  hydroxyalkyl group; or 
 a branched C 3 -C 4  hydroxyalkyl group; 
 
 
       or X 1  and X 2  form, together with the nitrogen atom that bears them, a saturated or unsaturated 5- to 7-membered heterocycle, wherein at least one ring member is optionally substituted with a heteroatom chosen from O, S, or N; and/or the heterocycle is optionally substituted with at least one linear or branched C 1 -C 4  alkyl or C 1 -C 4  hydroxyalkyl group. 
     
     
       9. The 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazin-7-amine compound according to  claim 1 , wherein R 1  and R 6  are identical and are chosen from a hydrogen atom or a C 1 -C 6  alkyl group, optionally terminating with one group chosen from a —NX 1 X 2  group or an —OH group,
 wherein X 1  and X 2  are independently chosen from:
 a linear C 1 -C 4  alkyl group; 
 a branched C 3 -C 4  alkyl group; 
 a linear C 1 -C 4  hydroxyalkyl group; or 
 a branched C 3 -C 4  hydroxyalkyl group; 
 
 
       or X 1  and X 2  form, together with the nitrogen atom that bears them, a saturated or unsaturated 5- to 7-membered heterocycle, wherein at least one ring member is optionally substituted with a heteroatom chosen from O, S, or N; and/or the heterocycle is optionally substituted with at least one linear or branched C 1 -C 4  alkyl or C 1 -C 4  hydroxyalkyl group. 
     
     
       10. The 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazin-7-amine compound according to  claim 1 , wherein the compound is chosen from: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         or the addition salts thereof, optical isomers thereof, geometrical isomers thereof, tautomers thereof, or solvates thereof. 
       
     
     
       11. The 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazin-7-amine compound according to  claim 1  wherein R 1  and R 6  are identical and are chosen from a C 1 -C 6  alkyl group interrupted with an oxygen atom or an NH group, and optionally terminated with at least one group chosen from an —NX 1 X 2  group or an —OH group,
 wherein X 1  and X 2  are independently chosen from:
 a linear C 1 -C 4  alkyl group; 
 a branched C 3 -C 4  alkyl group; 
 a linear C 1 -C 4  hydroxyalkyl group; or 
 a branched C 3 -C 4  hydroxyalkyl group; 
 
 
       or X 1  and X 2  form, together with the nitrogen atom that bears them, a saturated or unsaturated 5- to 7-membered heterocycle, wherein at least one ring member is optionally substituted with a heteroatom chosen from O, S, or N; and/or the heterocycle is optionally substituted with at least one linear or branched C 1 -C 4  alkyl or C 1 -C 4  hydroxyalkyl group. 
     
     
       12. The 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazin-7-amine compound according to  claim 1 , wherein the compound is chosen from: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         or the addition salts thereof, optical isomers thereof, geometrical isomers thereof, tautomers thereof, or solvates thereof. 
       
     
     
       13. The 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazin-7-amine compound according to  claim 1 , wherein R 1  and R 6  are different and are independently chosen from a hydrogen atom or a C 1 -C 6  alkyl group, optionally terminated with at least one group chosen from an NX 1 X 2  group or an OH group,
 wherein X 1  and X 2  are independently chosen from:
 a linear C 1 -C 4  alkyl group; 
 a branched C 3 -C 4  alkyl group; 
 a linear C 1 -C 4  hydroxyalkyl group; or 
 a branched C 3 -C 4  hydroxyalkyl group; 
 
 
       or X 1  and X 2  form, together with the nitrogen atom that bears them, a saturated or unsaturated 5- to 7-membered heterocycle, wherein at least one ring member is optionally substituted with a heteroatom chosen from O, S, or N; and/or the heterocycle is optionally substituted with at least one linear or branched C 1 -C 4  alkyl or C 1 -C 4  hydroxyalkyl group. 
     
     
       14. The 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazin-7-amine compound according to  claim 1 , wherein R 1  and R 6  are different and are independently chosen from a hydrogen atom or a C 1 -C 6  alkyl group, optionally terminated with an OH group. 
     
     
       15. The 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazin-7-amine compound according to  claim 1 , wherein the compound is chosen from: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         or the addition salts thereof, optical isomers thereof, geometrical isomers thereof, tautomers thereof, or solvates thereof. 
       
     
     
       16. A composition for dyeing keratin fibers, the composition comprising, in a medium that is suitable for dyeing keratin fibers, at least one 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazin-7-amine compound chosen from those of formula (I) or the addition salts thereof, the optical isomers or geometrical isomers thereof, or the tautomers and/or solvates thereof: 
       
         
           
           
               
               
           
         
       
       wherein:
 R 2 , R 3 , R 4 , R 5 , and R 7 , which are identical or different, are independently chosen from:
 a hydrogen or halogen atom; 
 a C 1 -C 4  alkyl group; 
 a C 1 -C 4  hydroxyalkyl group; 
 a carboxyl group; or 
 a (C 1 -C 4 )alkoxycarbonyl group; 
 
 R 1  and R 6 , which are identical or different, are chosen from:
 a hydrogen atom; or 
 a C 1 -C 10  or C 1 -C 6  alkyl group, optionally interrupted with at least one heteroatom chosen from O, S, or at least one —NR group, and/or optionally terminated with at least one —NX 1 X 2  group or a —OX 3  group, 
 
 X 1  and X 2 , which are identical or different, are independently chosen from:
 a hydrogen atom; 
 a linear C 1 -C 6  alkyl group; 
 a branched C 3 -C 6  alkyl group; 
 a linear C 1 -C 6  hydroxyalkyl group; or 
 a branched C 3 -C 6  hydroxyalkyl group; 
 
 or X 1  and X 2  form, together with the nitrogen atom that bears them, a saturated or unsaturated 5- to 8-membered heterocycle, wherein at least one ring member is optionally substituted with a heteroatom chosen from O, S, or N; and/or the heterocycle is optionally substituted with at least one linear or branched C 1 -C 4  alkyl or C 1 -C 4  hydroxyalkyl group; 
 X 3  is chosen from:
 a hydrogen atom; or 
 a linear C 1 -C 4  or branched C 3 -C 4  alkyl group; and 
 
 R is chosen from:
 a hydrogen atom; or 
 a linear C 1 -C 4  alkyl group. 
 
 
     
     
       17. The composition of  claim 16 , wherein the total amount of 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazin-7-amine compound ranges from about 0.001% to about 10% by weight, relative to the total weight of the composition. 
     
     
       18. The composition of  claim 16 , wherein the at least one 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazin-7-amine compound is chosen from: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         or the addition salts thereof, optical isomers thereof, geometrical isomers thereof, tautomers thereof, or solvates thereof. 
       
     
     
       19. A method for dyeing keratin fibers, the method comprising:
 applying to the keratin fibers, alone or in the presence of an oxidizing agent, a composition comprising at least one 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazin-7-amine compound chosen from those of formula (I) or the addition salts thereof, optical isomers thereof, geometrical isomers thereof, tautomers thereof, or solvates thereof: 
 
       
         
           
           
               
               
           
         
       
       wherein:
 R 2 , R 3 , R 4 , R 5 , and R 7 , which are identical or different, are independently chosen from:
 a hydrogen or halogen atom; 
 a C 1 -C 4  alkyl group; 
 a C 1 -C 4  hydroxyalkyl group; 
 a carboxyl group; or 
 a (C 1 -C 4 )alkoxycarbonyl group; 
 
 R 1  and R 6 , which are identical or different, are chosen from:
 a hydrogen atom; or 
 a C 1 -C 10  or C 1 -C 6  alkyl group; optionally interrupted with at least one heteroatom chosen from O, S, or at least one —NR group and/or optionally terminated with at least one —NX 1 X 2  group or —OX 3  group, 
 
 X 1  and X 2 , which are identical or different, are independently chosen from:
 a hydrogen atom; 
 a linear C 1 -C 6  alkyl group; 
 a branched C 3 -C 6  alkyl group; 
 a linear C 1 -C 6  hydroxyalkyl group; or 
 a branched C 3 -C 6  hydroxyalkyl group; 
 or X 1  and X 2  form, together with the nitrogen atom that bears them, a saturated or unsaturated 5- to 8-membered heterocycle, wherein at least one ring member is optionally substituted with a heteroatom chosen from O, S, or N; and/or the heterocycle is optionally substituted with at least one linear or branched C 1 -C 4  alkyl or C 1 -C 4  hydroxyalkyl group; 
 
 X 3  is chosen from:
 a hydrogen atom; or 
 a linear C 1 -C 4  or branched C 3 -C 4  alkyl group; and 
 
 R is chosen from:
 a hydrogen atom; or 
 a linear C 1 -C 4  alkyl group; and 
 
 leaving the composition on the fibers for a sufficient time to develop the desired color. 
 
     
     
       20. The method of  claim 19 , wherein the at least one 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazin-7-amine compound is chosen from: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         or the addition salts thereof, optical isomers thereof, geometrical isomers thereof, tautomers thereof, or solvates thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.